News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Solvay SA Delays U.S. Filing For Psychosis Drug
October 2, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
BRUSSELS, Sept 29 (Reuters) - Belgian drugs and chemicals maker Solvay's planned filing for U.S. approval for its psychosis drug Bifeprunox has been delayed until October, Solvay said on Friday.
>>>
Discuss This Story
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
MORE ON THIS TOPIC
Legal
REGENXBIO Secures Legal Win in Gene Therapy Patent Battle Vs. Sarepta
February 23, 2026
·
2 min read
·
Tristan Manalac
FDA
Makary, Prasad Under Fire as FDA Turmoil Reaches President Trump
February 20, 2026
·
6 min read
·
Heather McKenzie
Vaccines
ACIP Meeting Delayed as Turbulence Rocks CDC, US Vaccine Policy
February 20, 2026
·
2 min read
·
Tristan Manalac
Regulatory
FDA’s Top Drug Regulator To Probe Safety of Antidepressants, RSV Antibodies
February 20, 2026
·
2 min read
·
Tristan Manalac
